This report contains market size and forecasts of Targeted Drug EGFR RTK Inhibitors for NSCLC in Global, including the following market information:
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Targeted Drug EGFR RTK Inhibitors for NSCLC market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Icotinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Targeted Drug EGFR RTK Inhibitors for NSCLC include Beta Pharma, AstraZeneca, Natco Pharma, Qilu Pharmaceutical, Genentech (Roche Group), Mylan, Teva, OSI Pharmaceuticals and Glenmark Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Targeted Drug EGFR RTK Inhibitors for NSCLC companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment Percentages, by Type, 2021 (%)
Icotinib
Gefitinib
Erlotinib
Afatinib
Osimertinib
Brigatinib
Other
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment Percentages, by Application, 2021 (%)
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Targeted Drug EGFR RTK Inhibitors for NSCLC revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Targeted Drug EGFR RTK Inhibitors for NSCLC revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Beta Pharma
AstraZeneca
Natco Pharma
Qilu Pharmaceutical
Genentech (Roche Group)
Mylan
Teva
OSI Pharmaceuticals
Glenmark Pharmaceuticals
Beacon Pharmaceuticals
Boehringer Ingelheim
Pfizer
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Drug International Limted
Everest Pharmaceuticals
Incepta Pharmaceuticals Limited
Cipla Pharma
Dr Reddy's Laboratories
Zydus Cadila
Hetero Drugs
Intas Pharmaceuticals
Alkem Laboratories
RPG Life Sciences
Fresenius Kabi India